10-K: Oruka Therapeutics' 2024 10-K Filing Highlights Novel Antibody Development for Psoriasis and Immunology

Oruka Therapeutics' 2024 10-K filing outlines its focus on developing innovative monoclonal antibody therapies for psoriasis and other inflammatory and immunology conditions, with key programs ORKA-001 and ORKA-002 progressing towards clinical trials.

Summary

• Oruka Therapeutics is a clinical-stage biopharmaceutical company specializing in novel monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology (I&I) indications.
• The company's lead program, ORKA-001, targets the p19 subunit of interleukin-23 (IL-23p19) for psoriasis treatment, with Phase 1 trial dosing initiated in Q4 2024 and interim data expected in the second half of 2025.
• ORKA-002, the co-lead program, targets interleukin-17A and interleukin-17F (IL-17A/F) for psoriasis and psoriatic arthritis, with Phase 1 trial dosing planned for Q3 2025 and interim data expected in the first half of 2026.
• Oruka anticipates the development program for ORKA-001 from first-in-human to BLA filing could take six to seven years, but this timeline is subject to FDA review.
• The company's strategy involves applying antibody engineering to validated modes of action to improve efficacy and dosing convenience while reducing technical and biological risk.
• Oruka has a third mAb program, ORKA-003, targeting an undisclosed pathway, focused on inflammatory dermatology conditions.
• The company completed its acquisition of Pre-Merger Oruka on August 29, 2024, and changed its name from ARCA biopharma, Inc.
• As of February 28, 2025, Oruka had 36 full-time employees.
• The company had cash, cash equivalents, and marketable securities of $393.7 million as of December 31, 2024, which is expected to fund operations for at least twelve months.
• Oruka reported a net loss of $83.7 million for the period from February 6, 2024 (inception) to December 31, 2024.
• The company relies on license agreements with Paragon Therapeutics for ORKA-001 and ORKA-002, involving milestone payments and royalties.
• Oruka is subject to extensive government regulations, including FDA requirements for biologics and healthcare laws.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both the potential and the risks associated with Oruka's business. The focus on innovation and clinical development suggests a positive outlook, but the discussion of financial losses and regulatory challenges tempers the overall sentiment.

Positives

• Oruka's strategy focuses on antibody engineering to improve efficacy and convenience of existing therapies.
• The company has a third mAb program, ORKA-003, targeting an undisclosed pathway in inflammatory dermatology.
• As of December 31, 2024, Oruka had $393.7 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least twelve months.

Negatives

• Oruka reported a net loss of $83.7 million for the period from February 6, 2024 (inception) to December 31, 2024.
• The company relies on license agreements with Paragon Therapeutics for ORKA-001 and ORKA-002, involving milestone payments and royalties.

Risks

• Drug development and regulatory approval are costly, time-consuming, and uncertain.
• Oruka is substantially dependent on the success of ORKA-001 and ORKA-002.
• The company may not be able to meet requirements for the chemistry, manufacturing and control of its programs.
• Oruka faces competition from entities that have developed or may develop programs for the diseases addressed by its product candidates.
• The company may not be able to raise the capital that it needs to support its business plans.
• Raising additional capital may cause dilution to stockholders, restrict operations or require relinquishing rights to technologies or product candidates.
• Oruka's ability to obtain and protect its patents and other proprietary rights is uncertain.
• The company currently relies on agreements with third parties to develop its product candidates.
• Oruka's estimates of market opportunity and forecasts of market growth may prove to be inaccurate.
• The company's business is dependent on key personnel, and it will be harmed if it cannot recruit and retain highly qualified personnel.
• Significant disruptions of information technology systems or breaches of data security could adversely affect the company's business.
• Changes in and failures to comply with United States and foreign privacy and data protection laws, regulations and standards may adversely affect the company's business, operations and consolidated financial performance.
• The company may become exposed to costly and damaging liability claims and its insurance may not cover all damages from such claims.
• The company's business could be adversely affected by macroeconomic or geopolitical conditions.

Future Outlook

Oruka expects its existing cash, cash equivalents, and marketable securities will be sufficient to fund its operating plans for at least twelve months from the date of filing of this Annual Report. The company anticipates that its research and development and general and administrative costs will continue to increase significantly.

Management Comments

• Our name is derived from or, for skin, and arukah, for restoration, and reflects our mission to deliver therapies for chronic skin diseases that provide patients the most possible freedom from their condition.
• We believe that our focused strategy, differentiated portfolio, and deep expertise position us to set a new treatment standard in large I&I markets with continued unmet need.

Industry Context

The document highlights the competitive landscape of the biotechnology and biopharmaceutical industries, particularly in the treatment of psoriasis and psoriatic arthritis. It notes the presence of established biologics and oral medicines, emphasizing the need for innovation in efficacy and dosing frequency to achieve commercial success.

Comparison to Industry Standards

• The document compares Oruka's approach to existing therapies like Skyrizi and Bimzelx, aiming for higher PASI 100 rates and more convenient dosing regimens.
• It references the KNOCKOUT study, which used higher doses of risankizumab, and the GUIDE study, which showed longer treatment-free remissions with guselkumab, as benchmarks for ORKA-001's potential.
• The document mentions Enbrel, Humira, Stelara, Tremfya, Cosentyx, and Taltz as approved biologic therapies for psoriasis, and Otezla and Sotyktu as approved oral medicines, highlighting the competitive landscape.

Related Party Transactions

• The company relies on license agreements with Paragon Therapeutics for ORKA-001 and ORKA-002, involving milestone payments and royalties.
• Fairmount Funds Management LLC, a related party, has a representative on the Board and beneficially owns more than 5% of Paragon.
• The company issued a convertible note to Fairmount Healthcare Fund II, L.P., a related party, in March 2024.

Stakeholder Impact

• The company's activities aim to provide patients with chronic skin diseases greater freedom from their condition.
• The company's success depends on attracting, motivating, and retaining talent at all levels.
• The company's performance is subject to the risks and uncertainties of the biotechnology and biopharmaceutical industries.

Next Steps

• Share interim data from the Phase 1 trial of ORKA-001 in the second half of 2025.
• Initiate a Phase 2a proof-of-concept study of ORKA-001 in moderate-to-severe PsO in the second half of 2025.
• Share initial data from the Phase 2a trial in the second half of 2026.
• Initiate dosing of healthy volunteers in a Phase 1 trial of ORKA-002 in the third quarter of 2025.
• Share interim data from the first-in-human trial of ORKA-002 in the first half of 2026.
• Explore a sequential combination regimen of ORKA-002 and ORKA-001, called ORKA-021.

Key Dates